MethodsLiterature search. This meta

Methods
Literature search. This meta-analysis was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses statement 20 . Our metaanalysis searches were conducted using the PubMed, Web of Science Knowledge and
Cochrane Library databases from their inception dates to August 1, 2014. The search
applied the following search terms:‘‘rituximab’’,‘‘CD20’’,and‘‘nephroticsyndrome’’.

Study selection criteria and study types. RCTs or comparative cohort studies that
evaluated the efficacy and safety of rituximab in treating pediatric patients with
refractory NS were included.

Type of participants. The patients were diagnosed with NS at 18 years of age and
younger.

Type of interventions. Rituximab and current immunotherapy were compared.
Different schedules and modalities of rituximab were included.

Analyzed outcomes. The primary outcome was relapse-free survival. The secondary
outcomes were (1) complete remission events, (2) biological indicators, including
proteinuria, serum albumin, serum cholesterol and serum creatinine, and (3) adverse
events.

Hasil (Bahasa Indonesia) 2:

Metode
pencarian Sastra. Ini meta-analisis dilakukan sesuai dengan Preferred
Produk Pelaporan untuk Sistematik Ulasan dan Meta-Analisis pernyataan 20. Pencarian metaanalisis kami dilakukan dengan menggunakan PubMed, Web of Science Pengetahuan dan
Cochrane Library database dari tanggal awal mereka untuk 1 Agustus 2014. Pencarian
diterapkan istilah pencarian berikut: '' rituximab '', '' CD20 '', dan '' nephroticsyndrome ''. kriteria seleksi Studi dan jenis penelitian. RCT atau penelitian kohort komparatif yang mengevaluasi efikasi dan keamanan rituximab dalam mengobati pasien anak dengan NS refraktori dimasukkan. Jenis peserta. Para pasien didiagnosis dengan NS di usia 18 tahun dan lebih muda. Jenis intervensi. Rituximab dan imunoterapi saat dibandingkan. Jadwal yang berbeda dan modalitas rituximab dimasukkan. Hasil penelaahan. Hasil primer adalah kelangsungan hidup kambuh bebas. Sekunder hasil yang (1) peristiwa remisi lengkap, (2) indikator biologis, termasuk proteinuria, serum albumin, kolesterol serum dan kreatinin serum, dan (3) yang merugikan peristiwa.